Elizabeth (Lisa) Petri Henske is the Director of the Center for LAM Research and Clinical Care at Brigham and Women’s Hospital. She is Professor of Medicine at Harvard Medical School, an Associate Member of the Broad Institute of MIT and Harvard, and a practicing medical oncologist at the Dana-Farber Cancer Institute. She is a graduate of Yale University and Harvard Medical School and trained at the Massachusetts General Hospital in Internal Medicine and Hematology-Oncology. Dr. Henske’s laboratory discovered that lymphangioleiomyomatosis (LAM) is caused by mutations in the tuberous sclerosis complex (TSC) genes. She also was the first to discover that the TSC1 and TSC2 proteins physically interact. Her research laboratory is focused on the cellular, metabolic, and immunologic mechanisms underlying the pathogenesis of TSC and LAM, Birt-Hogg-Dube Syndrome (BHD), and chromophobe renal cell carcinoma (ChRCC). Her current interests include the role of the tumor immune microenvironment in the pathogenesis and therapy of TSC and the role of the TFEB/TFE3 transcription factors in TSC tumorigenesis. She is a member of the American Society for Clinical Investigation and the Association of American Physicians and serves on the Board of Directors of The LAM Foundation and the Professional Advisory Board of the Tuberous Sclerosis Alliance. Dr. Henske has received awards for her research from the Tuberous Sclerosis Alliance, The LAM Foundation, the American Thoracic Society, and the Society for Women’s Health Research (the Medtronic Prize). EHenske@BWH.Harvard.edu
Do you work at the Brigham? Having trouble with something and not sure who to ask?